Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Galenica AG ( (CH:GALE) ) has issued an update.
Galenica AG reported record group sales of CHF 4,135.6 million for 2025, a 5.5% increase driven by broad-based growth across all business areas, notably strong demand for prescription medicines – including GLP-1 weight-loss products – and nutritional supplements. The pharmacy network expanded to 381 locations and posted higher omni-channel sales and sharply rising paid health services, while wholesale, services and production, and logistics & IT all grew in line with or slightly above the Swiss market, and the newly created Diagnostics unit from the Labor Team acquisition contributed around 1% to sales growth. Management confirmed guidance for a 10–12% rise in EBIT for 2025 and signalled that the dividend should remain at least at the previous year’s level, underlining the group’s confidence in its integrated healthcare network and strengthened positioning in the Swiss pharmacy, wholesale and diagnostics markets, supported by a revamped sales reporting structure that better reflects its strategic focus.
The most recent analyst rating on (CH:GALE) stock is a Buy with a CHF108.00 price target. To see the full list of analyst forecasts on Galenica AG stock, see the CH:GALE Stock Forecast page.
More about Galenica AG
Galenica AG is a Swiss healthcare group listed on SIX Swiss Exchange that operates a nationwide network of pharmacies, pharmaceutical wholesale and logistics, proprietary consumer healthcare brands, diagnostics and home care services. With more than 8,000 employees, it focuses on serving the Swiss healthcare market through an integrated model that spans retail pharmacies (including omni-channel offerings), products and brands, logistics and IT, and specialised services such as home care and medication packaging.
Average Trading Volume: 107,384
Technical Sentiment Signal: Buy
Current Market Cap: CHF4.87B
See more data about GALE stock on TipRanks’ Stock Analysis page.